About Technology Issues FAQ

Links

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.